AR064235A1 - Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer - Google Patents

Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer

Info

Publication number
AR064235A1
AR064235A1 ARP070103285A ARP070103285A AR064235A1 AR 064235 A1 AR064235 A1 AR 064235A1 AR P070103285 A ARP070103285 A AR P070103285A AR P070103285 A ARP070103285 A AR P070103285A AR 064235 A1 AR064235 A1 AR 064235A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
independently
heterocycloalkyl
alkyl
cycloalkyl
Prior art date
Application number
ARP070103285A
Other languages
English (en)
Spanish (es)
Inventor
Stephen M Condon
Yijung Deng
Matthew G Laporte
Susan R Rippin
Original Assignee
Tetralogic Pharmaceuticals Cor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetralogic Pharmaceuticals Cor filed Critical Tetralogic Pharmaceuticals Cor
Publication of AR064235A1 publication Critical patent/AR064235A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
ARP070103285A 2006-07-24 2007-07-24 Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer AR064235A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82014106P 2006-07-24 2006-07-24

Publications (1)

Publication Number Publication Date
AR064235A1 true AR064235A1 (es) 2009-03-25

Family

ID=38896626

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103285A AR064235A1 (es) 2006-07-24 2007-07-24 Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer

Country Status (6)

Country Link
US (2) US8143426B2 (https=)
EP (1) EP2049524A2 (https=)
JP (1) JP5452223B2 (https=)
AR (1) AR064235A1 (https=)
CL (1) CL2007002166A1 (https=)
WO (1) WO2008014252A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
MX2007010371A (es) 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
NZ572531A (en) * 2006-05-05 2011-09-30 Univ Michigan Bivalent smac mimetics and the uses thereof
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
JP5835331B2 (ja) 2011-08-23 2015-12-24 日産自動車株式会社 燃料電池の発電特性推定装置
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
WO2014056867A1 (en) * 2012-10-11 2014-04-17 F. Hoffmann-La Roche Ag Azaindolines
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
JP2019514900A (ja) 2016-04-27 2019-06-06 メッドシャイン ディスカバリー インコーポレイテッド 新規な二価のｉａｐアンタゴニストとしてのベンズイミダゾール結合インドール化合物
WO2019080928A1 (zh) * 2017-10-27 2019-05-02 南京明德新药研发股份有限公司 一种iap拮抗剂的晶型及其制备方法
BR112020009369A2 (pt) 2017-11-13 2020-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd miméticos de smac usados como inibidores de iap e seus usos
KR20220006611A (ko) * 2019-05-10 2022-01-17 치아타이 티안큉 파마수티컬 그룹 주식회사 Iap 억제제로서의 smac 모방물의 결정 및 그 제조방법
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
US20230029259A1 (en) * 2019-12-02 2023-01-26 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
CA3248179A1 (en) * 2022-04-19 2023-10-26 Mindset Pharma Inc. Indoline derivatives used as serotonergic agents useful for the treatment of disorders associated with them

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) * 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
EP0049898B2 (en) * 1980-10-15 1991-08-14 Takeda Chemical Industries, Ltd. Method for immunochemical assay and kit therefor
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4525300A (en) * 1983-01-07 1985-06-25 Japanese Foundation For Cancer Research Human leukemia virus-related peptides, antibodies of the peptides and a process for production of the antibodies
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
CA1200416A (en) * 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4935493A (en) * 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5208007A (en) * 1988-11-22 1993-05-04 Board Of Regents Of The University Of Oklahoma Isotopic tracer composition and method for making and using same
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US5545719A (en) * 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JPH04167172A (ja) * 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
ES2130406T5 (es) * 1992-08-05 2003-12-16 Meito Sangyo Kk Material compuesto de pequeño diametro compuesto de carboxipolisacarido soluble en agua y oxido de hierro magnetico.
JP3401005B2 (ja) * 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5527775A (en) * 1994-10-13 1996-06-18 Enzon, Inc. Reduction of mammalian neoplasms with phospholipase A2 activating substances
US6187557B1 (en) * 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
US5786173A (en) * 1996-03-19 1998-07-28 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US5977311A (en) 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
US6110691A (en) * 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2004007529A2 (en) 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
AU2001293189A1 (en) 2000-09-29 2002-04-08 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
US20020160975A1 (en) * 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
JP2004531731A (ja) 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
WO2003018014A2 (en) 2001-08-23 2003-03-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
US20060258581A1 (en) * 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
US6911426B2 (en) * 2001-11-21 2005-06-28 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20080199439A1 (en) 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
EP1715882A4 (en) 2004-01-16 2009-04-08 Univ Michigan SMAC-PEPTIDOMIMETIKA AND ITS USES
BRPI0506883A (pt) 2004-01-16 2007-05-29 Univ Michigan miméticos de smac conformacionalmente comprimidos e seus usos
CN1953744A (zh) 2004-02-05 2007-04-25 诺瓦提斯公司 Dna拓扑异构酶抑制剂和iap抑制剂的组合
US20070217607A1 (en) 2004-02-15 2007-09-20 Matrixview Limited Repetition Coded Compression For Encrypting Highly Correlated Data
WO2005084317A2 (en) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
DK2253614T3 (da) 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
KR100984459B1 (ko) * 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
CA2573644A1 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
ES2475207T3 (es) * 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
MX2007010371A (es) * 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
US20070003535A1 (en) * 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
JP4954983B2 (ja) * 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2006128455A2 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
US7989441B2 (en) 2005-06-08 2011-08-02 Novartis Ag Organic compounds
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101374829A (zh) * 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
KR20080080131A (ko) * 2005-12-20 2008-09-02 노파르티스 아게 Ｉａｐ-억제제와 탁산의 조합물
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US7807699B2 (en) 2006-03-21 2010-10-05 Joyant Pharmaceuticals, Inc. Dimeric pyrrolidine amide-containing small molecule apoptosis promoters
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
NZ572531A (en) 2006-05-05 2011-09-30 Univ Michigan Bivalent smac mimetics and the uses thereof
CN101535300B (zh) * 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
BRPI0717411A2 (pt) 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
NZ577150A (en) * 2006-12-19 2012-04-27 Genentech Inc Imidazopyridine inhibitors of iap
JP5454943B2 (ja) * 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap

Also Published As

Publication number Publication date
WO2008014252A2 (en) 2008-01-31
US20080021066A1 (en) 2008-01-24
JP5452223B2 (ja) 2014-03-26
US8143426B2 (en) 2012-03-27
CL2007002166A1 (es) 2008-01-25
WO2008014252A3 (en) 2008-03-13
EP2049524A2 (en) 2009-04-22
JP2009544727A (ja) 2009-12-17
US20120157390A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
AR064235A1 (es) Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
AR063943A1 (es) Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
AR085852A1 (es) Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina y composiciones farmaceuticas que los contienen
AR043938A1 (es) Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
CO6351741A2 (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv
UY28240A1 (es) Fases cristalinas de un potente inhibidor de la hcv
AR070801A1 (es) Derivados pirimidin -piridina
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
CO6321289A2 (es) Compuestos de ester boronato y composiciones farmaceuticas de los mismos
AR047793A1 (es) Inhibidores de la serina proteasa ns-3 del vhc
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR077463A1 (es) Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
AR028474A1 (es) Un compuesto derivado heteroaromatico biciclico, su uso y una composicion farmaceutica que lo comprende
AR069309A1 (es) Derivados de imidazo[1,2-a] piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos.
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
AR073760A1 (es) Derivados heterociclicos y metodos de uso de los mismos
AR066528A1 (es) Peptidos inhibidores de la replicacion del virus de la hepatitis c
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
PE20090042A1 (es) Analogos de ciclopamina
AR076274A1 (es) Inhibidores del virus de la hepatitis c
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
ES2606197T3 (es) Moduladores pirrolidina de GPR40
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular

Legal Events

Date Code Title Description
FA Abandonment or withdrawal